Last reviewed · How we verify
NCT03032562
Respiratory Muscle Strength and Function in Neuromuscular Disorders and Chronic Obstructive Pulmonary Disease
trial testing Multimodal measurement of respiratory muscle function and strength in Respiratory Muscle Paralysis in 200 participants. Status unknown.
31 December 2019
Quick facts
| Lead sponsor | Universität Münster |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 December 2016 |
| Primary completion | 31 December 2019 |
| Estimated completion | 28 February 2020 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- Multimodal measurement of respiratory muscle function and strength
Conditions studied
- Respiratory Muscle Paralysis — all drugs for Respiratory Muscle Paralysis →
Sponsor
Universität Münster — full company profile →
Who can join
Adults 18 to 80, any sex, with Respiratory Muscle Paralysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Using an extensive set of both volitional and non-volitional tests of respiratory muscle function and strength it is the aim of this study to * identify disease-specific patterns of respiratory muscle impairment in different NMD and COPD * establish which set of tests is predictive of sleep-disordered breathing or daytime hypercapnia in patients with NMD or COPD, respectively. * to investigate the decline of respiratory muscle function in patients with progressive NMD and COPD along with sleep studies and capnography
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Respiratory Muscle Function Tests and Diaphragm Ultrasound Predict Nocturnal Hypoventilation in Slowly Progressive Myopathies.
Spiesshoefer J, Lutter R, Kabitz HJ, Henke C, et al · · 2021 · cited 9× · PMID 34721265 · DOI 10.3389/fneur.2021.731865
Verify or expand the search:
- PubMed search for NCT03032562
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Universität Münster trials
Trials by the same sponsor.
- NCT07197307 — Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · Phase 2 · not yet recruiting
- NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
- NCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodyna · Phase 1 · completed
- NCT06727851 — ESGE-Quality Improvement in Endoscopy: ERCP · enrolling by invitation
- NCT06021288 — Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI ) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03032562 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universität Münster
- Last refreshed: 26 January 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03032562.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing